Collaborations between Physicians and Industry - Effect of the 2012 Sunshine Law-Moderator: Allan May, Emergent Medical Partners; Panel: Gary Fanton & Peter Fitzgerald, MDs Stanford Univ & Faouzi Kallel, BSC-02/08/2011 - 6:00pm

Event Information
Event Topic: 
Collaborations between Physicians and Industry - Effect of the 2012 Sunshine Law
Event Date: 
02/08/2011 - 6:00pm
Event Location: 
Wilson Sonsini Goodrich & Rosati- 650 Page Mill Road, Palo Alto, CA
Speaker Information
Event Speaker: 
Moderator: Allan May, Emergent Medical Partners; Panel: Gary Fanton & Peter Fitzgerald, MDs Stanford Univ & Faouzi Kallel, BSC
Event Speaker Company: 
Event Speaker Bio: 

Allan May
Managing Director, Emergent Medical Partners

Allan is a founder of Life Science Angels (, the largest angel organization in the U.S. focused solely on early stage medical device and life science start-ups, and comprised solely of high net worth individuals from the medical device or biotech fields. In addition to over 100 serial entrepreneurs and founders, LSA membership includes a number of scientists, physicians and engineers with extensive life science credentials, 25 major venture capital firms specializing in life science investments, and 20 sponsors, compromising many of the premier organizations focused on providing services to the life science industry. Since 2005, LSA has invested $30M in 30 early stage companies, attracted in excess of $600M in contemporary or follow-on venture capital, and achieved two favorable exits, with one portfolio company in IPO registration.

In 2007, Allan joined renowned inventor, entrepreneur and cardiac surgeon, Dr. Thomas Fogarty, in co-founding Emergent Medical Partners, solely focused on early stage medical device company creation and investing. EMP has made 16 investments to date.

He is Chairman of the Board of the Kauffman Foundation’s Angel Capital Education Foundation, a nonprofit devoted to the study of angel investing. In addition, he has founded or invested in over 50 medtech and biotech startups, and lectures frequently on trends and developments affecting early stage biotech and life science investing. He is also a member of the editorial board of In Vivo, and speaks frequently on trends and developments affecting biotech and life science investing.

Gary Fanton, MD Stanford University
Dr. Gary Fanton is the Chief of the Section of Sports Medicine at Stanford’s Department of Orthopedic Surgery. He is Board Certified by the American Board of Orthopedic Surgery and is currently the Team Physician in Orthopedics for the San Francisco 49ers.

Dr. Fanton was a co-founder and board member of Oratec Interventions, a medical device start-up for minimally invasive spine and joint procedures that went public in April, 2000, which was subsequently purchased by Smith-Nephew in 2002. He actively serves on the medical advisory board for several public and private surgical device companies in the orthopedic industry and continues to design and develop unique surgical devices for minimally invasive surgery. He has co-authored several device patents and has several others pending.

Peter Fitzgerald, MD Stanford University
Dr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. Dr. Fitzgerald’s laboratory includes 14 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 95 clinical trials, published over 300 manuscripts/chapters, and lectures worldwide. Peter has been principal/founder of eleven medical device companies and transitioned eight of these to large medical device companies. In 2001, Peter co-founded LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco.

Faouzi Kallel, PhD is a Fellow/Sr Manager of Pre-Clinical Research at Boston Scientific. Faouzi has over 15 years of medical device experience in small, large companies and academia. Prior to joining BSC, he was a Director of Clinical Research and Scientific Affairs at Micrus Endovascular. Prior to that, Faouzi was with AFx (a start-up company acquired by Guidant) where he assumed management positions in R&D and clinical marketing supporting the development of new minimally invasive surgical techniques for the treatment of cardiac arrhythmia. Before his tenure in the medical device industry, he was a research faculty member at the University of Texas Medical School where he pioneered the development of a new imaging modality called elastography, a technique that enabled the imaging of tissue elasticity. Faouzi received a bachelor of science in Electrical Engineering and a master of science and a Ph.D. in Biomedical Engineering from the University of Montreal in Canada.

Event Details
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Event Details: 

In 2012 the Sunshine Act will take effect, requiring yearly reporting of all compensation from manufacturers to physicians over a cumulative value of $100.
Many expect that the Sunshine Act will have the biggest impact on medical device companies, as they are much more reliant on physician input during product development than other industry segments. Indeed, as In Vivo recently noted, “… most of the ideas for new device technologies have come, directly or indirectly, from physicians themselves.“
This panel will explore the potential effect of the Sunshine Act on the physician/industry relationship going forward. We will hear from an expert panel of physicians who have held leadership roles in medical device firms discussing key questions, such as:
• How will this new approach effect the development of better drugs and devices?
• How will access to this information effect the practice patterns of health care providers, if at all?
• Will physicians be deterred from consulting to industry?
• What new practices will medical device companies need to implement in order to maintain their dialogue with medical personnel?